Fundraising Fox

Jasper Therapeutics

NASDAQ: JSPR

Redwood City, US · Delaware corporation · 4 known investors

Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company is running clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma.

Founders & leadership

JS
Judith ShizuruFounder
HCHerb Cross
Herb CrossExecutive
JMJeet Mahal
Jeet MahalExecutive
PCPatrick Crutcher
Patrick CrutcherNamed on SEC filing
SLSvetlana Lucas
Svetlana LucasNamed on SEC filing
WS
Wenru SongNamed on SEC filing
GF
Gregory F. KeenanNamed on SEC filing

Board

KVKurt von Emster
Kurt von EmsterinBoard MemberManaging Partner at Abingworth
TWThomas Wiggans
Thomas WiggansBoard director
ME
Matthew E. RosBoard director

Investors · 4

Reported raises · per SEC filings

Form D private placements

$132M disclosed across 1 round · 2026

$132MraisedAug 2026 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Herb CrossExecutive Officer
  • Jeet MahalExecutive Officer, Director
  • Patrick CrutcherDirector
  • Thomas WiggansDirector
  • Judith ShizuruDirector
  • Svetlana LucasDirector
  • Kurt von EmsterDirector
  • Wenru SongExecutive Officer
  • Gregory F. KeenanExecutive Officer
  • Matthew E. RosDirector
Offering amount
$132M
Amount sold
$132M
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Companies competing with Jasper Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Jasper Therapeutics do?
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company is running clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma.
Who founded Jasper Therapeutics?
Jasper Therapeutics was founded by Judith Shizuru.
Who are Jasper Therapeutics's investors?
Jasper Therapeutics's investors include Avego BioScience Capital, TSVC, Abingworth, Ikarian Capital.
How much funding has Jasper Therapeutics raised?
Jasper Therapeutics has disclosed $132M raised across 1 round.
Where is Jasper Therapeutics headquartered?
Jasper Therapeutics is headquartered in Redwood City, US.